Medication info
Itrex Rosuvastatin Calcium Tablet 10mg

Itrex Rosuvastatin Calcium Tablet 10mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
Domestic - 30 tablets/bottle, Export - 30 tablets/box [10 tablets/(Alu-Alu x 3)]
Approval status
Active

MFDS item code 201400287 · Approved 2014.01.22 · Insurance code 698502550

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is needed. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not use in patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • type III primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct to dietary changes when diet and exercise alone are inadequate for the control of primary hypercholesterolemia and mixed dyslipidemia patients. Additionally, it is prescribed as an adjunct therapy for patients with homozygous familial hypercholesterolemia along with other lipid-lowering treatments. It has been shown to effectively lower total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It is also used as an adjunctive therapy in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia when their LDL cholesterol levels exceed certain criteria. This drug also aids patients with type III primary dysbetalipoproteinemia and is utilized to reduce the risk of stroke, myocardial infarction, and arterial revascularization in elderly patients at high cardiovascular risk. In summary, this medication is effectively used for various forms of hypercholesterolemia and for reducing the risk of cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is needed. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not use in patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to any component of this drug, have active liver disease, have muscle disorders, take certain immunosuppressants, have severe kidney dysfunction, or are pregnant or breastfeeding should not take this medication. Furthermore, high doses are prohibited in patients at high risk of muscle damage. This medication contains lactose, so individuals with lactose intolerance or related genetic disorders should avoid it. Patients with a history of liver disease or excessive alcohol consumption should have regular liver function tests and use this drug with caution. If symptoms of myalgia or muscle weakness occur, patients should immediately inform their healthcare provider and undergo necessary examinations. This medication may increase blood sugar levels in some patients, so those at risk for diabetes should regularly monitor their blood sugar levels. Patients with certain genetic characteristics may have different drug responses, so dosage adjustments may be necessary. This drug can cause severe skin reactions, so if abnormal skin symptoms occur, it should be discontinued immediately. When used in conjunction with other medications, interactions may increase the blood concentration of this drug or the risk of side effects, so it is essential to inform the healthcare provider about any other medications being taken. The use of this medication during pregnancy or breastfeeding should be avoided as it may pose risks to the fetus or infant. In the case of overdose, there are no specific antidotes, so treatment should proceed based on the symptoms, and liver function and muscle enzyme levels should be monitored. This medication does not significantly impact driving or machinery operation, but caution is advised as dizziness may occur. Adverse reactions reported during drug use include headache, dizziness, dyspepsia, myalgia, skin rashes, etc., and if these symptoms are severe, medical consultation is necessary. The blood concentration of this medication may be higher in Asians, so caution is needed when determining dosage.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug eruption resembling lichen planus, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

Domestic - 30 tablets/bottle, Export - 30 tablets/box [10 tablets/(Alu-Alu x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.